← All organizations
Highest phase reached
Phase 4
First clinical trial
Nov 1, 2001First marketed drug
Feb 27, 2008First NDA
Feb 27, 2008Last known activity
Mar 31, 2026
Timeline
1980s
- Jan 1, 1988
Regeneron— Founded
2010s
- Aug 3, 2012
aflibercept— Marketing Organization
2020s
- Apr 19, 2022
Checkmate Pharmaceuticals— Acquired
- Aug 18, 2023
pozelimab— NDA Organization
- Aug 18, 2023
pozelimab— NDA Secondary Org
- Sep 25, 2023
Decibel Therapeutics— Acquired
Drugs by trial phase (223 distinct, 646 trials)
Phase 4 (24 own, 0 via acquisition)
Phase 3 (83 own, 5 via acquisition)
Phase 2 (61 own, 2 via acquisition)
Phase 1 (45 own, 2 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
- Abdominal Pain
- Acute Coronary Syndrome
- Adenocarcinoma
- Adenocarcinoma of Lung
- Anemia
- Anemia, Aplastic
- Arteritis
- Arthritis
- Arthritis, Juvenile
- Arthritis, Rheumatoid
- Ascites
- Aspergillosis
- Aspergillosis, Allergic Bronchopulmonary
- Asthma
- Atherosclerosis
- Back Pain
- Basal Cell Carcinoma
- Burns
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Cardiovascular Diseases
- Cataract
- Central Nervous System Neoplasms
- Central Serous Chorioretinopathy
- Choroidal Neovascularization
- Colorectal Neoplasms
- Communicable Diseases
- Corneal Neovascularization
- Coronary Artery Disease
- Coronavirus Infections
- Cryopyrin-Associated Periodic Syndromes
- Deafness
- Dermatitis
- Dermatitis, Allergic Contact
- Dermatitis, Atopic
- Dermatitis, Contact
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Diabetic Retinopathy
- Disease Progression
- Dissociative Disorders
- Dyslipidemias
- Eczema
- Edema
- Endometrial Neoplasms
- Enteritis
- Eosinophilia
- Eosinophilic Esophagitis
- Esophagitis
- Eye Diseases
- Fallopian Tube Neoplasms
- Gastritis
- Gastroenteritis
- Genetic Diseases, Inborn
- Giant Cell Arteritis
- Glaucoma
- Glaucoma, Neovascular
- Glioma
- Gout
- Graves Ophthalmopathy
- Hearing Loss
- Hemoglobinuria
- Hemoglobinuria, Paroxysmal
- Hemorrhage
- Hepatitis
- Hepatitis B
- Hodgkin Disease
- Hypercholesterolemia
- Hyperlipidemias
- Hyperlipoproteinemia Type II
- Hypersensitivity
- Hypersensitivity, Immediate
- Hypertension
- Hypertriglyceridemia
- Immune System Diseases
- Infarction
- Infections
- Inflammation
- Intestinal Diseases
- Intracranial Arteriosclerosis
- Keratoconjunctivitis
- Kidney Diseases
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lipodystrophy
- Lipodystrophy, Congenital Generalized
- Low Back Pain
- Lung Diseases
- Lung Diseases, Obstructive
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Macular Degeneration
- Macular Edema
- Melanoma
Marketed drugs (11)
Subsidiaries (2 direct, 2 total across the full acquisition tree)
Recent trials (50)
- NCT05164250Lead sponsorN/A—
- NCT07301450Lead sponsorN/A—
- NCT04617535Lead sponsorN/A—
- NCT04776694Lead sponsorN/A—
- NCT05232110Lead sponsorN/A—
- NCT04710056Lead sponsorN/A—
- NCT05619367Lead sponsorN/A—
- NCT06028594Lead sponsorN/A—
- NCT06063746Lead sponsorN/A—
- NCT06132191Lead sponsorN/A—
- NCT06500598Lead sponsorN/A—
- NCT06631677Lead sponsorN/A—
- NCT05906706Lead sponsorN/A—
- NCT06003881Lead sponsorN/A—
- NCT03576690Study directorN/A—
Details
- Founded
- Tarrytown, NY, US Jan 1, 1988
- First NDA
- Feb 27, 2008
- Last known activity
- Mar 31, 2026
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy